Table 1 Demographic and clinical characteristics of healthy subjects and patients with JSLE.
Healthy controls Number (%/range) | JSLE Number (%/range) | p-value | |
|---|---|---|---|
Total number | 66 | 45 | – |
Female:male | 45:21 | 33:12 | 0.67 |
Median age (years) | 19.5 (15.2–32.2) | 21.4 (15.4–29.8) | 0.26 |
Ethnicity (%) | |||
White | 32 (48%) | 17 (38%) | 0.33 |
Black | 5 (8%) | 7 (16%) | 0.22 |
South Asian | 12 (18%) | 13 (29%) | 0.25 |
East Asian | 11 (17%) | 3 (7%) | 0.15 |
Other | 6 (9%) | 5 (11%) | 0.75 |
Disease activity | |||
Median disease duration (years) | – | 8.7 | – |
Median age at onset (years) | – | 12.4 | – |
Global BILAG = 0 | – | 34 (76%) | – |
Global BILAG = 1 (1 score C) | – | 4 (9%) | – |
Global BILAG = 8 (1 score B) | – | 3 (7%) | – |
Global BILAG = 9 (1 score B + 1 score C) | – | 2 (4%) | – |
Global BILAG = 18 (2 scores B + 1 score C) | – | 1 (2%) | – |
Global BILAG = 24 (3 scores B) | – | 1 (2%) | – |
Average SLEDAI | – | 1.9 (0–10) | – |
SLEDAI = 0 | – | 25 (56%) | – |
SLEDAI = 2–4 | – | 14 (31%) | – |
SLEDAI = 6–10 | – | 6 (13%) | – |
Median serology (NR = normal range) | |||
Anti-dsDNA (IU/mL) (NR = < 50) | – | 28.0 | – |
C3 (g/L) (NR = 0.9–1.8) | – | 1.09 | – |
Lymphocyte count (109/L) (NR = 1.2–3.5) | – | 1.57 | – |
Treatment | |||
None | – | 4 (9%) | – |
Rituximab in the past year | – | 0 (0%) | – |
Rituximab ever | – | 12 (27%) | – |
Average duration since last rituximab treatment (years) | – | 4.7 | – |
Hydroxychloroquine | – | 38 (84%) | – |
Methotrexate | – | 5 (11%) | – |
Azathioprine | – | 8 (18%) | – |
Mycophenolate Mofetil | – | 19 (42%) | – |
Prednisolone (any dose) | – | 11 (24%) | – |
Prednisolone ≥ 10 mg/day | – | 6 (13%) | – |
Cyclophosphamide in the past year | – | 1 (2%) | – |
